helmholtzeyeinstituteРоссийский офтальмологический журналRussian Ophthalmological Journal2072-00762587-5760Real time Publishers10.21516/2072-0076-2021-14-2-81-84helmholtzeyeinstitute-664Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWSПрименение оптической когерентной томографии у пациентов с соматотропинпродуцирующей аденомой гипофизаOptical coherence tomography in patients with somatotropin-producing pituitary adenomaГавриловаН. А.GavrilovaN. A.

Наталья Александровна Гаврилова — д-р мед. наук, профессор, зав. кафедрой глазных болезней

ул. Делегатская, д. 20, стр. 1, Москва, 127486

Natalia A. Gavrilova— Dr. of Med. Sci., professor, head of chair of eye diseases

20, Bldg. 1, Delegatskaya St., Moscow, 127473

ГаджиеваН. С.GadzhievaN. S.

Нурия Саниевна Гаджиева— канд. мед. наук, доцент кафедры глазных болезней

ул. Делегатская, д. 20, стр. 1, Москва, 127486

Nuriа S. Gadzhieva— Cand. of Med. Sci., assistant of professor of chair of eye diseases

20, Bldg. 1, Delegatskaya St., Moscow, 127473

КузьминаА. В.Kuz’minaA. V.

Анастасия Владимировна Кузьмина — аспирант кафедры глазных болезней

ул. Делегатская, д. 20, стр. 1, Москва, 127486

Anastasiya V. Kuz’mina — PhD student, chair of eye diseases

20, Bldg. 1, Delegatskaya St., Moscow, 127473

ФГБОУ ВО «МГМСУ им. А.И. Евдокимова» Минздрава РоссииРоссияA.I. Evdokimov Moscow State Medical University of Medicine and DentistryRussian Federation2021200620211428184Copyright © Гаврилова Н.А., Гаджиева Н.С., Кузьмина А.В., 20212021Гаврилова Н.А., Гаджиева Н.С., Кузьмина А.В.Gavrilova N.A., Gadzhieva N.S., Kuz’mina A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://roj.igb.ru/jour/article/view/664

Оптическая когерентная томография (ОКТ) нашла широкое применение в офтальмологической практике. В обзоре представлены результаты ОКТ у пациентов с соматотропинпродуцирующей аденомой гипофиза — соматотропиномой, гормонально-активной опухолью аденогипофиза. Данная опухоль секретирует избыточное количество соматотропного гормона (СТГ), стимулирующего секрецию инсулиноподобного фактора роста I типа. Механизм действия СТГ (проангиогенное действие, стимуляция пролиферации и миграции эндотелиальных клеток, развитие эндотелиальной дисфункции и отека сетчатки) обусловливает безусловный интерес к изучению результатов обследования пациентов с соматотропиномами с помощью современных методов диагностики, таких как ОКТ.

Optical coherence tomography (OCT) is widely used in ophthalmological practice. The review presents the results of OCT in patients with somatotropin-producing pituitary adenoma, or somatotropinoma, which is a hormone-active tumor of the adenohypophysis, characterized by excessive production of somatotropic hormone (STH). It stimulates the secretion of type I insulin-like growth factor (IGF-I). The mechanisms of STH action (pro-angiogenic action, stimulation endothelial cell proliferation and migration, development of endothelial dysfunction and retinal edema) requires much attention to the results of examination of patients with somatotropinomas using modern diagnostic methods, such as OCT.

оптическая когерентная томографиясоматотропиномадиагностикаoptical coherence tomographysomatotropinomadiagnosticsReferencesДудина М.А., Догадин С.А., Лобынцева Л.А., Гайдук К.К., Боровик О.В. Содержание соматотропного гормона и инсулиноподобного фактора роста I в крови и их взаимосвязь с объемом соматотропиномы гипофиза у больных акромегалией. Сибирское медицинское обозрение. 2012; 73 (1): 15–8.Dudina M.A., Dogadin S.A., Lobyntseva L.A., Gayduk K.K., Borovik O.V.Concentration of somatotropin and insulin-like growth factor-1 in blood, relation with pituitary somatotropinoma size in patients with acromegaly. Siberian medical review. 2012; 73 (1): 15–8 (in Russian)].Tjörnstrand A., Gunnarsson K., Evert M., et al.The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011. Eur. J. Endocrinol. 2014; 171 (4): 519–26. doi: 10.1530/eje-14-0144Tjörnstrand A., Gunnarsson K., Evert M., et al.The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011. Eur. J. Endocrinol. 2014; 171 (4): 519–26. doi: 10.1530/eje-14-0144Mehta G.U., Lonser R.R. Management of hormone-secreting pituitary adenomas. Neuro Oncol. 2017; 19 (6): 762–73. doi:10.1093/neuonc/now130Mehta G.U., Lonser R.R. Management of hormone-secreting pituitary adenomas. Neuro Oncol. 2017; 19 (6): 762–73. doi:10.1093/neuonc/now130Agustsson T.T., Baldvinsdottir T., Jonasson J.G., et al. The epidemiology of pituitary adenomas in Iceland, 1955–2012: a nationwide population-based study. Eur. J. Endocrinol. 2015; 173 (5): 655–64. doi:10.1530/eje-15-0189Agustsson T.T., Baldvinsdottir T., Jonasson J.G., et al. The epidemiology of pituitary adenomas in Iceland, 1955–2012: a nationwide population-based study. Eur. J. Endocrinol. 2015; 173 (5): 655–64. doi:10.1530/eje-15-0189Воротникова С.Ю., Пигарова Е.А., Дзеранова Л.К.Метаболические эффекты гормона роста. Ожирение и метаболизм. 2011; 4: 55–9.Vorotnikova S.Yu., Pigarova E.A., Dzeranova L.K. Metabolic effects of growth hormone. Obesity and metabolism. 2012; 73 (1): 15–8 (in Russian). doi: 10.14341/2071-8713-5308Саркисов Д.С. Структурные основы адаптации и компенсации нарушен-ных функций. Москва: Медицина; 1987.Sarkisov D.S. Structural bases of adaptation and compensation of impaired functions. Moscow: Meditsina; 1987 (in Russian).Dekkers O.M., Biermasz N.R., Pereira A.M., Romijn J.A., Vandenbroucke J.P. Mortality in acromegaly: A metaanalysis. J. Clin. Endocrinol. Metab. 2008; 93 (1): 61–7. doi:10.1210/jc.2007-1191Dekkers O.M., Biermasz N.R., Pereira A.M., Romijn J.A., Vandenbroucke J.P. Mortality in acromegaly: A metaanalysis. J. Clin. Endocrinol. Metab. 2008; 93 (1): 61–7. doi:10.1210/jc.2007-1191Rajasoorya C., Holdaway I.M., Wrightson P., Scott D.J., Ibbertson H.K. Determinants of clinical outcome and survival in acromegaly. Clin. Endocrinol. (Oxf). 1994; 41 (1): 95–102. doi:10.1111/j.1365-2265.1994.tb03789.xRajasoorya C., Holdaway I.M., Wrightson P., Scott D.J., Ibbertson H.K. Determinants of clinical outcome and survival in acromegaly. Clin. Endocrinol. (Oxf). 1994; 41 (1): 95–102. doi:10.1111/j.1365-2265.1994.tb03789.xMaffei P., Dassie F., Wennberg A., Parolin M., Vettor R. The Endothelium in Acromegaly. Front Endocrinol (Lausanne). 2019; 10: 437. doi:10.3389/fendo.2019.00437Maffei P., Dassie F., Wennberg A., Parolin M., Vettor R. The Endothelium in Acromegaly. Front Endocrinol (Lausanne). 2019; 10: 437. doi:10.3389/fendo.2019.00437Wilson S.H., Davis M.I., Caballero S., Grant M.B.Modulation of retinal endothelial cell behaviour by insulin-like growth factor I and somatostatin analogues: implications for diabetic retinopathy. Growth hormone IGF Res. 2001; 11 (A): 53–9. doi:10.1016/S1096-6374(01)80009-5Wilson S.H., Davis M.I., Caballero S., Grant M.B.Modulation of retinal endothelial cell behaviour by insulin-like growth factor I and somatostatin analogues: implications for diabetic retinopathy. Growth hormone IGF Res. 2001; 11 (A): 53–9. doi:10.1016/S1096-6374(01)80009-5Spoerri P.E., Caballero S., Wilson S.H., Shaw L.C., Grant M.B.Expression of IGFBP-3 by human retinal endothelial cell cultures: IGFBP-3 involvement in growth inhibition and apoptosis. Invest. Ophthalmol. Vis. Sci. 2003; 44: 365–9. doi:10.1167/iovs.02-0309Spoerri P.E., Caballero S., Wilson S.H., Shaw L.C., Grant M.B.Expression of IGFBP-3 by human retinal endothelial cell cultures: IGFBP-3 involvement in growth inhibition and apoptosis. Invest. Ophthalmol. Vis. Sci. 2003; 44: 365–9. doi:10.1167/iovs.02-0309Messias de Lima C.F., dos Santos Reis M.D., da Silva Ramos F.W., Ayres-Martins S.,Smaniotto S.Growth hormone modulates in vitro endothelial cell migration and formation of capillary-like structures. Cell. Biol. Int. 2017; 41: 577–84. doi:10.1002/cbin.10747Messias de Lima C.F., dos Santos Reis M.D., da Silva Ramos F.W., Ayres-Martins S.,Smaniotto S.Growth hormone modulates in vitro endothelial cell migration and formation of capillary-like structures. Cell. Biol. Int. 2017; 41: 577–84. doi:10.1002/cbin.10747King G.L., Goodman A.D., Buzney S., Moses A., Kahn C.R.Receptors and growth-promoting effects of insulin and insulin like growth factors on cells from bovine retinal capillaries and aorta. J. Clin. Inves. 1985; 75 (3): 1028–36. doi:10.1172/JCI111764King G.L., Goodman A.D., Buzney S., Moses A., Kahn C.R.Receptors and growth-promoting effects of insulin and insulin like growth factors on cells from bovine retinal capillaries and aorta. J. Clin. Inves. 1985; 75 (3): 1028–36. doi:10.1172/JCI111764Lambooij A.C., van Wely K.H., Lindenbergh-Kortleve D.J., et al.Insulinlike growth factor-I and its receptor in neovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2003; 44: 2192–8. doi:10.1167/iovs.02-0410Lambooij A.C., van Wely K.H., Lindenbergh-Kortleve D.J., et al.Insulinlike growth factor-I and its receptor in neovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2003; 44: 2192–8. doi:10.1167/iovs.02-0410Chu Q., Moreland R., Yew N.S., et al. Systemic Insulin-like growth factor-1 reverses hypoalgesia and improves mobility in a mouse model of diabetic peripheral neuropathy. Mol. Ther. 2008; 16: 1400–8. doi: 10.1038/mt.2008.115Chu Q., Moreland R., Yew N.S., et al. Systemic Insulin-like growth factor-1 reverses hypoalgesia and improves mobility in a mouse model of diabetic peripheral neuropathy. Mol. Ther. 2008; 16: 1400–8. doi: 10.1038/mt.2008.115Новиков В.Е., Пожилова Е.В., Левченкова О.С.Перспективы применения ингибиторов фактора адаптации к гипоксии в медицинской практике. Обзоры по клинической фармакологии и лекарственной терапии. 2015; 3: 9–17.Novikov V.E., Pozhilova E.V., Levchenkova O.S. Medical clinical perspectives of the hypoxia adaptation factor inhibitors. Reviews on Clinical Pharmacology and Drug Therapy. 2015; 3: 9–7 (in Russian)]. doi: 10.17816/RCF1339-17Кац М.В. Роль ИФР-I в неоваскуляризации сетчатки. Вестник СМУ 2018; 3 (22): 74. [Kats M.V.The role of IGF-I in retinal neovascularization. Bulletin of SMU. 2018; 3 (22): 74 (in Russian)].Кац М.В. Роль ИФР-I в неоваскуляризации сетчатки. Вестник СМУ 2018; 3 (22): 74. [Kats M.V.The role of IGF-I in retinal neovascularization. Bulletin of SMU. 2018; 3 (22): 74 (in Russian)].Onnis B., Rapisarda A., Melillo G. Development of HIF-1 42. Inhibitors for cancer therapy. J. Cell. Mol. Med. 2009; 13 (9A): 2780–6. doi: 10.1111 / j.1582-4934.2009.00876.xOnnis B., Rapisarda A., Melillo G. Development of HIF-1 42. Inhibitors for cancer therapy. J. Cell. Mol. Med. 2009; 13 (9A): 2780–6. doi: 10.1111 / j.1582-4934.2009.00876.xPunglia R.S., Lu M., Hsu J., et al. Regulation of Vascular Endothelial Growth Factor expression by Insulin-Like Growth Factor I. Diabetes. 1997; 46 (10): 1619–26. doi:10.2337/diacare.46.10.1619Punglia R.S., Lu M., Hsu J., et al. Regulation of Vascular Endothelial Growth Factor expression by Insulin-Like Growth Factor I. Diabetes. 1997; 46 (10): 1619–26. doi:10.2337/diacare.46.10.1619Spraul C.W., Kaven C., Amann J., Lang G.K., Lang G.E.Effect of Insulin-Like Growth Factors 1 and 2, and glucose on the migration and proliferation of bovine retinal pigment epithelial cells in vitro. Ophthalmic Res. 2000; 32: 244–8. doi: 10.1159/000055621Spraul C.W., Kaven C., Amann J., Lang G.K., Lang G.E.Effect of Insulin-Like Growth Factors 1 and 2, and glucose on the migration and proliferation of bovine retinal pigment epithelial cells in vitro. Ophthalmic Res. 2000; 32: 244–8. doi: 10.1159/000055621Füchtbauer L., Olsson D., Coopmans E., et al.Increased number of retinal vessels in acromegaly. European Journal of Endocrinology. 2020; 182 (3): 293–302. doi: 10.1530/EJE-19-0778Füchtbauer L., Olsson D., Coopmans E., et al.Increased number of retinal vessels in acromegaly. European Journal of Endocrinology. 2020; 182 (3): 293–302. doi: 10.1530/EJE-19-0778Boulton M., Gregor Z., McLeod D., et al. Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management. Br. J. Ophthalmol. 1997; 81: 228–33. doi:10.1136/bjo.81.3.228Boulton M., Gregor Z., McLeod D., et al. Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management. Br. J. Ophthalmol. 1997; 81: 228–33. doi:10.1136/bjo.81.3.228Meyer-Schwickerath R., Pfeiffer A., Blum W.F., et al. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. J. Clin. Invest. 1993; 92: 2620–5. doi:10.1172/jci116877Meyer-Schwickerath R., Pfeiffer A., Blum W.F., et al. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. J. Clin. Invest. 1993; 92: 2620–5. doi:10.1172/jci116877Waldbillig R.J., Jones B.E., Schoen T.J., et al.Vitreal insulin-like growth factor binding proteins (IGFBPs) are increased in human and animal diabetics. Curr. Eye Res. 1994; 13: 539–46. doi:10.3109/02713689408999886Waldbillig R.J., Jones B.E., Schoen T.J., et al.Vitreal insulin-like growth factor binding proteins (IGFBPs) are increased in human and animal diabetics. Curr. Eye Res. 1994; 13: 539–46. doi:10.3109/02713689408999886van Setten G., Brismar K., Algvere P.Elevated intraocular levels of insulin-like growth factor I in a diabetic patient with acromegaly. Orbit. 2002; 21: 161–7. doi:10.1076/orbi.21.2.161.7186van Setten G., Brismar K., Algvere P.Elevated intraocular levels of insulin-like growth factor I in a diabetic patient with acromegaly. Orbit. 2002; 21: 161–7. doi:10.1076/orbi.21.2.161.7186Danis R.P., Bingaman D.P. Insulin-like Growth Factor-1 retinal microangiopathy in the pig eye. Ophthalmology.1997; 104 (10): 1661–9. doi:10.1016/s0161-6420(97)30081-5Danis R.P., Bingaman D.P. Insulin-like Growth Factor-1 retinal microangiopathy in the pig eye. Ophthalmology.1997; 104 (10): 1661–9. doi:10.1016/s0161-6420(97)30081-5Hussain M.A., Studer K., Messmer E.P., Froesch E.R.Treatment with insulin-like growth factor I alters capillary permeability in skin and retina. Diabetes. 1995; 44: 1209–12. doi:10.2337/diabetes.44.10.1209Hussain M.A., Studer K., Messmer E.P., Froesch E.R.Treatment with insulin-like growth factor I alters capillary permeability in skin and retina. Diabetes. 1995; 44: 1209–12. doi:10.2337/diabetes.44.10.1209Lange M., Pagotto U., Hopfner U., et al.Endothelin expression in normal human anterior pituitaries and pituitary adenomas. The Journal of Clinical Endocrinology Metabolism. 1994; 79 (6): 1864–70. doi:10.1210/jcem.79.6.7527415Lange M., Pagotto U., Hopfner U., et al.Endothelin expression in normal human anterior pituitaries and pituitary adenomas. The Journal of Clinical Endocrinology Metabolism. 1994; 79 (6): 1864–70. doi:10.1210/jcem.79.6.7527415Stewart D.J.Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease. Annals of internal medicine. 1991; 114: 464–9. doi: 10.7326/0003-4819-114-6-464Stewart D.J.Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease. Annals of internal medicine. 1991; 114: 464–9. doi: 10.7326/0003-4819-114-6-464Cioffi G.A., Orgul S., Onda E., Bacon D.R., Van Buskirk E.M. An in vivo model of chronic optic nerve ischemia: the dose-dependent effects of endothelin-1 on the optic nerve microvasculature. Curr. Eye Res. 1995; 14: 1147–53. doi:10.3109/02713689508995821Cioffi G.A., Orgul S., Onda E., Bacon D.R., Van Buskirk E.M. An in vivo model of chronic optic nerve ischemia: the dose-dependent effects of endothelin-1 on the optic nerve microvasculature. Curr. Eye Res. 1995; 14: 1147–53. doi:10.3109/02713689508995821Nishimura K., Riva C.E., Harino S., et al.Effects of endothelin-1 on optic nerve head blood flow in cats. J. Ocul. Pharmacol. Ther.1996; 12: 75–83. doi:10.1089/jop.1996.12.75Nishimura K., Riva C.E., Harino S., et al.Effects of endothelin-1 on optic nerve head blood flow in cats. J. Ocul. Pharmacol. Ther.1996; 12: 75–83. doi:10.1089/jop.1996.12.75Emdadi A., Zangwill L., Sample P.A., et al.Patterns of optic disk damage in patients with early focal visual field loss. Am. J. Ophthalmol. 1998; 126: 763–71. doi:10.1016/s0002-9394(98)00281-5Emdadi A., Zangwill L., Sample P.A., et al.Patterns of optic disk damage in patients with early focal visual field loss. Am. J. Ophthalmol. 1998; 126: 763–71. doi:10.1016/s0002-9394(98)00281-5Cioffi G.A.Ischemic model of optic nerve injury. Trans Am. Ophthalmol. Soc. 2005; 103: 592–613. doi:10.1016/j.ajo.2006.02.013Cioffi G.A.Ischemic model of optic nerve injury. Trans Am. Ophthalmol. Soc. 2005; 103: 592–613. doi:10.1016/j.ajo.2006.02.013Ciresi A., Amato M.C., Morreale D., et al. Cornea in acromegalic patients as a possible target of growth hormone action. J. Endocrinol. Invest. 2011; 34: 30–5. doi:10.1007/BF03347058Ciresi A., Amato M.C., Morreale D., et al. Cornea in acromegalic patients as a possible target of growth hormone action. J. Endocrinol. Invest. 2011; 34: 30–5. doi:10.1007/BF03347058Polat S.B., Ugurlu N., Ersoy R., et al.Evaluation of central corneal and central retinal thicknesses and intraocular pressure in acromegaly patients. Pituitary. 2014; 17: 327–32. doi:10.1007/s11102-013-0505-1Polat S.B., Ugurlu N., Ersoy R., et al.Evaluation of central corneal and central retinal thicknesses and intraocular pressure in acromegaly patients. Pituitary. 2014; 17: 327–32. doi:10.1007/s11102-013-0505-1Pekel G., Akin F., Ertürk M.S., et al.Chorio-retinal thickness measurements in patients with acromegaly. Eye (Lond). 2014; 28 (11): 1350–4. doi:10.1038/eye.2014.216Pekel G., Akin F., Ertürk M.S., et al.Chorio-retinal thickness measurements in patients with acromegaly. Eye (Lond). 2014; 28 (11): 1350–4. doi:10.1038/eye.2014.216Zhang X., Ma J., Wang Y., et al.Elevated serum IGF-1 level enhances retinal and choroidal thickness in untreated acromegaly patients. Endocrine. 2018; 59: 634–42. doi:10.1007/s12020-017-1511-2Zhang X., Ma J., Wang Y., et al.Elevated serum IGF-1 level enhances retinal and choroidal thickness in untreated acromegaly patients. Endocrine. 2018; 59: 634–42. doi:10.1007/s12020-017-1511-2Yazgan S., Arpaci D., Celik H.U., Isik I. Evaluation of macular and peripapillary choroidal thickness, macular volume and retinal nerve fiber layer in acromegaly patients. Int. Ophthalmol. 2018; 38: 617–25. doi:10.1007/s10792-017-0500-zYazgan S., Arpaci D., Celik H.U., Isik I. Evaluation of macular and peripapillary choroidal thickness, macular volume and retinal nerve fiber layer in acromegaly patients. Int. Ophthalmol. 2018; 38: 617–25. doi:10.1007/s10792-017-0500-zSen E., Tutuncu Y., Elgin U., et al. Comparing acromegalic patients to healthy controls with respect to intraocular pressure, central corneal thickness, and optic disc topography findings. Indian J. Ophthalmol. 2014; 62 (8): 841–5. doi:10.4103/0301-4738.141035Sen E., Tutuncu Y., Elgin U., et al. Comparing acromegalic patients to healthy controls with respect to intraocular pressure, central corneal thickness, and optic disc topography findings. Indian J. Ophthalmol. 2014; 62 (8): 841–5. doi:10.4103/0301-4738.141035Cennamo G., Auriemma R.S., Cardone D., et al. Evaluation of the retinal nerve fibre layer and ganglion cell complex thickness in pituitary macroadenomas without optic chiasmal compression. Eye. 2015; 29 (6): 797–802. doi: 10.1038/eye.2015.35Cennamo G., Auriemma R.S., Cardone D., et al. Evaluation of the retinal nerve fibre layer and ganglion cell complex thickness in pituitary macroadenomas without optic chiasmal compression. Eye. 2015; 29 (6): 797–802. doi: 10.1038/eye.2015.35Duru N., Ersoy R., Altinkaynak H., et al. Evaluation of retinal nerve fiber layer thickness in acromegalic patients using Spectral-Domain Optical Coherence Tomography. Seminars in Ophthalmology. 2016; 31 (3): 285–90. doi:10.3109/08820538.2014.962165Duru N., Ersoy R., Altinkaynak H., et al. Evaluation of retinal nerve fiber layer thickness in acromegalic patients using Spectral-Domain Optical Coherence Tomography. Seminars in Ophthalmology. 2016; 31 (3): 285–90. doi:10.3109/08820538.2014.962165Şahin M., Şahin A., KılınçF., et al.Retina ganglion cell/inner plexiform layer and peripapillary nerve fiber layer thickness in patients with acromegaly. Int. Ophthalmol. 2017; 37: 591–8. doi: 10.1007/s10792-016-0310-8Şahin M., Şahin A., KılınçF., et al.Retina ganglion cell/inner plexiform layer and peripapillary nerve fiber layer thickness in patients with acromegaly. Int. Ophthalmol. 2017; 37: 591–8. doi: 10.1007/s10792-016-0310-8

The authors declare that there are no conflicts of interest present.